Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
NCT04368273Phase 2Unknown
- Sponsor
- Peking University Third Hospital
- Start
- May 2020
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in Cervical Cancer (CC), sponsored by Peking University Third Hospital. Status: unknown.
02
Drugs
toripalimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04368273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04368273.